The Prognostic Role of Diagnostic Criteria for COVID-19-Associated Pulmonary Aspergillosis: A Cross-Sectional Retrospective Study
by
,
Erika Asperges
1,*,
Rebecca Pesare
1,2,
Cecilia Bassoli
1,2,
Matteo Calia
1,2,
Sonia Lerta
1,2,
Francesco Citiolo
2,
Giuseppe Albi
3,
Caterina Cavanna
4,
Paolo Sacchi
1 and
Raffaele Bruno
1,2
1
S.C. Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
2
Department of Clinical-Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy
3
Department of Electrical, Computer and Biomedical Engineering, University of Pavia, 27100 Pavia, Italy
4
Microbiology and Virology Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
*
Author to whom correspondence should be addressed.
Antibiotics 2024, 13(2), 150; https://doi.org/10.3390/antibiotics13020150
Submission received: 30 December 2023
/
Revised: 27 January 2024
/
Accepted: 1 February 2024
/
Published: 3 February 2024
Abstract
:Several criteria exist to diagnose pulmonary aspergillosis with varying degrees of certainty in specific populations, including oncohaematological patients (EORTC/MSG), ICU patients (mAspICU) and COVID-19 patients (ECMM). At the beginning of the pandemic, however, the diagnosis of COVID-19-Associated Pulmonary Aspergillosis (CAPA) could not be performed easily, and the decision to treat (DTT) was empirical. In this cross-sectional retrospective study including patients with SARS-CoV-2 infection and suspicion of CAPA, we studied the concordance between the DTT and the three diagnostic criteria using Cohen’s coefficient, and then we identified the factors associated with the DTT and corrected them by treatment to study the influence of the diagnostic criteria on survival. We showed good concordance of the DTT and mAspICU and ECMM criteria, with “compatible signs”, “positive culture” and “positive galactomannan” influencing the DTT. Treatment also showed a positive effect on survival once corrected for a putative, possible or probable diagnosis of CAPA using mAspICU and ECMM criteria. We conclude that EORTC/MSGERC are not considered applicable in clinical practice due to the lack of inclusion of signs and symptoms and do not lead to improved survival. mAspICU and ECMM criteria showed a good degree of agreement with the DTT and a positive correlation with patient recovery.
1. Introduction
COVID-19-Associated Pulmonary Aspergillosis (CAPA) is an opportunistic infection associated with severe COVID-19. It was recognised as a clinical entity soon after the beginning of the pandemic, with a wildly varying incidence (5.7–35.0%) [1,2,3] and prevalence (3.0–33.3%) [4,5] depending on the diagnostic criteria.
Specific criteria for the diagnosis of invasive aspergillosis have existed since 2002, when the first European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria were compiled. The original article and its revisions propose three levels of certainty in the diagnosis of invasive aspergillosis (proven, probable and possible), and their intended use is aimed at research, not clinical practice [6,7,8]. Moreover, they focus on immunosuppressed patients (solid organ and haematopoietic stem-cell transplant recipients and solid cancer and haematological patients), with only the “proven” category being applicable to everyone, and thus their applicability to intensive care unit (ICU) and COVID-19 patients is limited [9].
Since then, efforts have been made to either expand these criteria to ICU patients [9] or to create new ones, like the AspICU algorithm [10], which has a more clinical focus and includes critically ill patients. The AspICU criteria distinguish patients with proven, putative pulmonary aspergillosis and colonisation. Later, Schauwvlieghe et al. modified the criteria (“modified AspICU”; mAspICU going forward), excluding the host factors (neutropenia, oncohaematological malignancy, glucocorticoid treatment and congenital or acquired immunosuppression) [11]. Their aim was to avoid the automatic exclusion from a diagnosis of invasive aspergillosis of critically ill patients with influenza, who rarely have host factors but are nonetheless at high risk of aspergillosis [12]. Since then, Influenza Associated Pulmonary Aspergillosis (IAPA) has been recognised as a clinical entity with its own dignity.
Finally, the European Confederation of Medical Mycology (ECMM) provided criteria specific to COVID-19 patients in 2020 [13]. The ECMM criteria are specifically targeted at both research and clinical guidance and were derived from EORTC/MSG and AspICU criteria. SARS-CoV-2 positivity and need for intensive care were considered entry criteria, and aspergillosis diagnosis was divided into proven, probable and possible.
mAspICU and ECMM criteria might seem similar at first glance since the main difference is COVID-19 as an entry factor in ECMM. However, ECMM also added factors specific to aspergillar tracheobronchitis, simplified the clinical factors and mandated slightly more specificity on the microbiological factors. Moreover, the entry factor “need for intensive care” of ECMM is different from the entry factor of “ICU patient” of mAspICU: it allows more flexibility, given that COVID-19 patients that required intensive care at the beginning of the pandemic were not necessarily admitted to the ICU due to bed unavailability, and consequently, they were often treated in ordinary or sub-intensive wards.
A summary of definitions of EORTC/MSG, mAspICU and ECMM criteria is provided in Supplementary Table S1, while a comparison of probable, possible, putative and colonisation diagnoses is provided in Table S2.
Especially at the beginning of the pandemic, when specific diagnostic criteria were not available, and procedures like lung biopsy and bronchoalveolar lavage (BAL) were limited, the decision to treat (DTT) was often empirical or based on knowledge derived from older diagnostic algorithms (EORTC/MSG and AspICU/mAspICU) despite suspicions of their inadequacy. The main aim of our study is to retrospectively assess the concordance between DTT and the three criteria (EORTC/MSG, mAspICU and ECMM). While other criteria have been developed in the meantime (for example, BM-aspICU [14]), these have been widely validated and disseminated and are likely to be used frequently in clinical practice. We also aim to identify which of their factors are associated with the DTT. We then correct by treatment to study the influence of the diagnostic criteria on survival.
2. Results
2.1. Population
As described in Table 1, we retrospectively collected 196 patients with COVID-19 and a suspicion of CAPA. The median age was 64 years old (53–71). There were 139 male and 57 female patients. The median length of hospital stay was 26.1 days (14.3–49.0). Death was recorded for 66 patients (33.7%). ICU admission was recorded for 52 patients (44.8%), and mechanical ventilation (invasive and non-invasive) was needed for 65 patients (57.0%).
2.1.1. mAspICU and ECMM Criteria
According to the mAspICU criteria, aspergillosis was certain in 0% of patients and putative in 18.0%. Colonisation was diagnosed in 1.8% of patients.
According to the ECMM criteria, aspergillosis was certain in 0% of patients, probable in 17.1% and possible in 1.8%.
The most prevalent host factors (applied as described in paragraph 4.4 and Table 1) were “use of steroids” (87.5%) and “presence of compatible signs” (74.1%).
2.1.2. EORTC/MSG Criteria
According to the criteria, aspergillosis was certain in 0% of patients, probable in 9.0% and possible in 24.3%. The most prevalent host factor was the use of steroids (32.7%).
2.1.3. Common Factors and Treatment
The main radiological pattern was atypical (83.8%), and galactomannan positivity was achieved in only 14.8% of patients. Aspergillus was cultured in 34 patients (30.4%). The DTT was applied in 33 patients (16.8%), mainly with voriconazole alone (24 patients, 12.2%).
2.2. Concordance of Diagnostic Criteria with the Decision to Treat
The 2 × 2 tables featuring the DTT and each of the three diagnostic criteria are shown in Table 2. Concordance among the DTT and the criteria is shown in Table 3. Cohen’s κ coefficient is 0.46 and 0.44 for mAspICU and ECMM criteria, respectively, showing good concordance with the DTT (p < 0.001 for both analyses), while it is only 0.16 for EORTC/MSG criteria (p > 0.05). A further comparison between mAspICU and ECMM criteria showed almost complete concordance (κ = 0.91, p < 0.001).
Factors Influencing the Decision to Treat
The logistic regression on criteria and their factors influencing the DTT was performed on 112 patients (who had available data on criteria factors and on treatment). The univariate analysis showed a significant influence of factors “compatible signs” and “positive galactomannan” (Table 4).
2.3. Correlation between Survival and Diagnostic Criteria
The logistic regression on criteria and their factors influencing survival was performed on 112 patients. The univariate analysis (Table 5) showed a significant association of mortality with cytotoxic agents and B-cell suppressants therapy. However, as shown in Table 6, when adjusted for the three diagnostic criteria (and cytotoxic agents and B-cell suppressants), treatment showed a significant association with survival when using mAspICU and ECMM criteria (OR 6.17 and 5.36, respectively; p < 0.05) but not EORTC/MSG (OR 3.80, p = 0.05).
3. Discussion
In our cohort of 196 patients, we found a prevalence of probable/possible/putative CAPA of 8.9–24.1% according to the criteria. No certain cases of CAPA were found; we attribute this to the difficulties in performing invasive procedures such as lung biopsy during the pandemic and in critically ill patients. The long median length of hospital stays, as well as the high rates of mechanical ventilation, ICU admission and death, were expected, given that our population included patients with severe COVID-19 before any knowledge on treatment or management became available. The prevalence of the male sex was also expected, as it is a known risk factor for severe COVID-19. Moreover, biological differences between males and females in immune response to fungal infections have been hypothesised and might have played a role [15].
We found a good agreement between the physicians’ DTT and the classification of patients according to mAspICU and ECMM diagnostic criteria. The factors that led to the DTT were the “presence of compatible signs” and “positive galactomannan”.
Both “compatible signs” and “positive galactomannan” are used by the mAspICU and ECMM criteria but not by the EORTC/MSG criteria, which, in fact, did not show concordance with the DTT. Moreover, the mAspICU and ECMM criteria showed almost perfect concordance between them.
Concerning survival, treatment showed a positive effect that was confirmed once corrected for a putative, possible or probable diagnosis of CAPA using mAspICU and ECMM criteria but not using EORTC/MSG.
The inappropriateness of the EORTC/MSG criteria for the diagnosis of CAPA has been suspected since the start of the pandemic. This was reasonable since the EORTC/MSG criteria were developed specifically for oncohaematological patients, while the AspICU/mAspICU and ECMM criteria were destined for ICU and COVID-19 patients. This inappropriateness has also been confirmed by the only other study we could find that compared the criteria for the diagnosis of CAPA [16]. The study was conducted in Germany on 684 critically ill patients and compared EORTC/MSG and mAspICU criteria, finding a Cohen’s κ of 0.14, which is comparable to our finding. Unfortunately, the analysis did not include ECMM criteria.
The concordance between mAspICU and ECMM criteria was less expected. In fact, the first reports of CAPA based on AspICU or mAspICU criteria led to an overestimation of its prevalence (up to 30%) [1,17], and even though larger studies brought this number down to 3.8% [18], they still advocated for a low threshold of suspicion, with the consequent risk of overtreatment. The development of the ECMM criteria had the effect of reducing the prevalence despite being based mostly on expert opinion and low-grade evidence [19], but variable incidence and prevalence are still reported [4,20]. Our work showed that the choice of starting a treatment does not rely on those factors that differ between the two criteria (the host factors) but on clinical presentation and microbiological factors. In fact, even though the microbiological factors of the ECMM are more stringent than those of mAspICU, the difference is minimal. This restricts the disagreement in management that would derive from the use of one diagnostic criterion over the other. This is further confirmed by our findings on survival: if treatment had been based on mAspICU or ECMM classification, it would have led to improved odds of survival (OR > 5, p < 0.05). The use of EORTC/MSG, on the other hand, would have still led to improved survival, with the OR being 3.80 and the lower limit of the confidence interval being >1, but it did not reach statistical significance.
A possible explanation of the inadequacy of the EORTC/MSG criteria lies in the restrictive nature of their host factors, which leave out not only non-oncohaematologial causes of immune suppression (for example, chronic inflammatory bowel diseases) but also other alterations of the immune system function that could still impact on the risk of opportunistic infections, like the use of anti-interleukin drugs. In this regard, tocilizumab is noteworthy because of its use in COVID-19. However, we point out that while tocilizumab might have an impact on the development of invasive aspergillosis, our results were not impacted by its use because only one patient in our cohort received it.
We did not find any literature on the effect of criteria on the DTT or their correlation to survival, although a Belgian study conducted on ICU patients found that, when CAPA is diagnosed with ECMM criteria, the additional presence of EORTC/MSG host factors leads to increased mortality [21].
Our study presents several limitations: apart from its single-centre and retrospective nature, the risk of selection bias is apparent in our assumption that patients with a suspicion of CAPA would have undergone at least one galactomannan antigen test. Another bias is our definition of a patient requiring the ICU, but since this study includes the first waves of the pandemic, where ICU beds were scarcely available and ordinary wards functioned as ICU units [22], we believe that this did not overly affect the results. In fact, patients needing non-invasive mechanical ventilation are still often treated in ordinary wards thanks to the skills acquired during the pandemic.
Prospective international studies on the impact of diagnostic criteria on accuracy and patients’ outcomes should be planned.
4. Materials and Methods
4.1. Study Design and Setting
We conducted a cross-sectional retrospective study including patients admitted to Fondazione IRCCS Policlinico San Matteo of Pavia from 21 February 2020 to 30 April 2022. All patients were hospitalised for a PCR-proven SARS-CoV-2 infection and were suspected of having CAPA.
4.2. Demographic and Clinical Data
Demographic and clinical data were retrospectively extracted from electronic medical records. The demographic data included age and gender; clinical data included wards of stay, date of admission and discharge, host risk factors for immunosuppressive condition according to aspergillosis diagnostic criteria, other relevant comorbidities, the use of invasive or non-invasive mechanical ventilation and clinical outcome. Microbiological data included fungal cultures and galactomannan (GM) antigen results from any sample. Chest X-rays or computed tomography (CT) results were reported as “normal” or with “typical” and “atypical” alterations. Antifungal therapy choice was also collected. Ninety-one patients had at least one missing value.
4.3. Laboratory and Radiological Investigations
Regarding laboratory investigations, we considered any galactomannan index ≥0.5 positive, regardless of a biological sample, in accordance with the manufacturer’s recommendations. This cutoff was suggested as the best compromise between specificity and sensitivity, with a relatively higher cutoff level (≥0.7) recommended only in special populations, such as patients receiving fungus-derived antibiotics or children receiving antineoplastic chemotherapy [23]. For assignation to the criteria, however, we used the cut-offs suggested by the criteria themselves (see Table S1. For example, serum galactomannan ≥1.0 for probable aspergillosis according to EORTC/MSG or serum galactomannan ≥0.5 for putative aspergillosis according to mAspICU).
Culture testing for Aspergillus species was performed in all patients in whom representative material from the lower respiratory tract could be collected.
The radiological definitions were derived from the criteria themselves (see Table S1). Typical radiological patterns, evidenced on X-ray or CT-scan examinations, include the following: dense, well-circumscribed lesion(s) with or without halo sign; air crescent sign; a cavity; or segmental or lobar consolidation. These typical signs are uncommon in non-neutropenic patients. Atypical radiological patterns refer to the presence of elements like unspecific infiltrates, diffuse ground-glass opacity and consolidations.
4.4. Cases’ Definitions According to Criteria
Patients were classified as cases of CAPA according to EORTC/MSG, mAspICU and ECMM criteria with a few modifications:
- -
- EORTC/MSG host factors related to an immunosuppressive condition [8] were applied as standard, but we equated prolonged use of dexamethasone or methylprednisolone prescribed for SARS-CoV-2 pneumonia to prolonged, high-dose of prednisone (≥0.3 mg/kg for more than 3 weeks).
- -
- Among the AspICU criteria, we chose the modified AspICU (mAspICU) [11], applied as standard. However, the entry factor “ICU admission” was also considered present in patients receiving mechanical ventilation in ordinary wards since these patients would have been admitted to the ICU prior to the pandemic.
- -
- ECMM criteria were applied faithfully [13].
4.5. Statistical Analysis
The patients’ clinical numerical characteristics were presented as median and interquartile ranges after the Shapiro test excluded the normal hypothesis, while categorical variables were presented with frequencies and percentages.
The concordance analyses between the three criteria and the DTT (defined as the physician’s decision to assign an antifungal treatment to the patient) and the agreement between the criteria themselves required the first step of making the criteria binary. Patients who could not be assigned to a diagnostic category within a given criterion (for example, for lack of the entry factor) or who were assigned to the “colonisation” category were given a value of 0, while patients assigned to the possible, probable or putative categories were given a value of 1. We then built 2 × 2 tables with the binary categories and the DTT. From these tables, we calculated Cohen’s κ coefficient and its p-value with the z-test. Cohen’s κ coefficient is used to quantify agreement between two evaluators. Similar to correlation coefficients, κ ranges from −1 to +1, where 0 expresses the amount of agreement that can be expected from random chance, a κ value < 0 can be interpreted as no agreement, while a value >0 indicates agreement. Positive values > 0.4 are usually interpreted as good concordance and >0.8 as excellent concordance.
We then evaluated with a univariate analysis the differences between the factors used to compile the diagnostic criteria, after dividing the study cohort according to the DTT. We used the non-parametric Mann–Whitney test to compare the numerical variables and the Chi-square or Fisher’s exact test, when appropriate, to compare the categorical variables binarised in 0/1 values. The same univariate analysis was repeated for the outcome of “survival”.
Finally, we assessed via a multivariate analysis the possible association between survival and the use of mAspICU, ECMM and EORTC/MSG criteria. We used logistic regression and included the criteria as predictors and the DTT variable as an additional confounding factor. Results of the multivariable analysis are reported as odds ratio (OR) and 95% confidence interval.
All the statistical tests were conducted two-tails, and a p-value < 0.05 was considered significant. Rstudio 4.0.5. with R version 4.1.2 was used for all the computation and statistical analysis.
4.6. Informed Consent and Ethical Concerns
All patients provided informed consent for the use of clinical data for scientific purposes according to hospital policy. Administrative data about our hospital’s COVID-19 patients are collected in a registry (SMACORE) approved by the Fondazione IRCCS Policlinico San Matteo’s ethics committee with protocol number 20200046877.
5. Conclusions
The evidence gathered in this study demonstrates that mAspICU and ECMM criteria have a good degree of agreement with the DTT and between themselves. Moreover, they show a positive correlation with patient recovery, further validating their use in daily clinical practice.
On the other hand, the use of EORTC/MSGERC criteria to guide the diagnosis is not considered applicable in clinical practice by physicians due to the lack of inclusion of clinical signs and symptoms. When antifungal therapy is prescribed according to its categories, it does not lead to improved survival.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics13020150/s1, Table S1: EORTC/MSGERC, mAspICU and ECMM criteria definitions; Table S2: comparison of probable/putative, possible and colonisation diagnosis.
Author Contributions
Conceptualization, E.A.; methodology, G.A. and P.S.; software, G.A.; validation, C.C., P.S. and R.B.; formal analysis, G.A.; investigation, F.C., R.P., C.B., M.C. and C.C.; resources, R.B.; data curation, F.C., R.P., C.B., M.C. and S.L.; writing—original draft preparation, E.A., F.C., R.P., C.B. and M.C.; writing—review and editing, P.S., C.C. and R.B.; visualisation, G.A.; supervision, E.A. and P.S.; project administration, R.B. All authors have read and agreed to the published version of the manuscript.
Funding
The Authors would like to acknowledge that part of this work has been financed by the European Union—Next Generation EU and Ministry of University and Research—MUR through the project Proliferation, Resistance and Infection Dynamics in Epidemics (PRIDE)—2022LP77J4—CUP F53D23000630006.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and the collection of data under the SMACORE database was approved by the Institutional Review Board (or Ethics Committee) of Fondazione IRCCS Policlinico San Matteo (protocol code 20200046877).
Informed Consent Statement
All patients provided informed consent for the use of clinical data for scientific purposes according to hospital policy.
Data Availability Statement
The data presented in this study are available upon request from the corresponding author.
Acknowledgments
We thank the patients and their families.
Conflicts of Interest
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. An abstract of these results was presented at the conference “11th Advances Against Aspergillosis & Mucormycosis”, 25–27 January 2024, Milan (Italy).
References
- Rutsaert, L.; Steinfort, N.; Van Hunsel, T.; Bomans, P.; Naesens, R.; Mertes, H.; Dits, H.; Van Regenmortel, N. COVID-19-associated invasive pulmonary aspergillosis. Ann. Intensive Care 2020, 10, 71. [Google Scholar] [CrossRef]
- Bartoletti, M.; Pascale, R.; Cricca, M.; Rinaldi, M.; Maccaro, A.; Bussini, L.; Fornaro, G.; Tonetti, T.; Pizzilli, G.; Francalanci, E.; et al. Epidemiology of Invasive Pulmonary Aspergillosis among Intubated Patients with COVID-19: A Prospective Study. Clin. Infect. Dis. 2021, 73, e3606–e3614. [Google Scholar] [CrossRef]
- Dellière, S.; Dudoignon, E.; Fodil, S.; Voicu, S.; Collet, M.; Oillic, P.A.; Salmona, M.; Dépret, F.; Ghelfenstein-Ferreira, T.; Plaud, B.; et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: A French multicentric retrospective cohort. Clin. Microbiol. Infect. 2020, 27, 790.e1–790.e5. [Google Scholar] [CrossRef]
- Prattes, J.; Wauters, J.; Giacobbe, D.R.; Lagrou, K.; Hoenigl, M.; ECMM-CAPA Study Group. Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: Results from a European confederation of medical mycology registry. Intensive Care Med. 2021, 47, 1158–1160. [Google Scholar] [CrossRef] [PubMed]
- Prattes, J.; Wauters, J.; Giacobbe, D.R.; Salmanton-García, J.; Maertens, J.; Bourgeois, M.; Reynders, M.; Rutsaert, L.; Van Regenmortel, N.; Lormans, P.; et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—A multinational observational study by the European Confederation of Medical Mycology. Clin. Microbiol. Infect. 2022, 28, 580–587. [Google Scholar] [CrossRef] [PubMed]
- Ascioglu, S.; Rex, J.H.; de Pauw, B.; Bennett, J.E.; Bille, J.; Crokaert, F.; Denning, D.W.; Donnelly, J.P.; Edwards, J.E.; Erjavec, Z.; et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin. Infect. Dis. 2002, 34, 7–14. [Google Scholar] [CrossRef]
- De Pauw, B.; Walsh, T.J.; Donnelly, J.P.; Stevens, D.A.; Edwards, J.E.; Calandra, T.; Pappas, P.G.; Maertens, J.; Lortholary, O.; Kauffman, C.A.; et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008, 46, 1813–1821. [Google Scholar] [CrossRef]
- Donnelly, J.P.; Chen, S.C.; Kauffman, C.A.; Steinbach, W.J.; Baddley, J.W.; Verweij, P.E.; Clancy, C.J.; Wingard, J.R.; Lockhart, S.R.; Groll, A.H.; et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin. Infect. Dis. 2020, 71, 1367–1376. [Google Scholar] [CrossRef]
- Bassetti, M.; Azoulay, E.; Kullberg, B.J.; Ruhnke, M.; Shoham, S.; Vazquez, J.; Giacobbe, D.R.; Calandra, T. EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. Clin. Infect. Dis. 2021, 72 (Suppl. S2), S121–S127. [Google Scholar] [CrossRef] [PubMed]
- Blot, S.I.; Taccone, F.S.; Van den Abeele, A.M.; Bulpa, P.; Meersseman, W.; Brusselaers, N.; Dimopoulos, G.; Paiva, J.A.; Misset, B.; Rello, J.; et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am. J. Respir. Crit. Care Med. 2012, 186, 56–64, Erratum in Am. J. Respir. Crit. Care Med. 2012, 186, 808. [Google Scholar] [CrossRef]
- Schauwvlieghe, A.F.A.D.; Rijnders, B.J.A.; Philips, N.; Verwijs, R.; Vanderbeke, L.; Van Tienen, C.; Lagrou, K.; Verweij, P.E.; Van de Veerdonk, F.L.; Gommers, D.; et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study. Lancet Respir. Med. 2018, 6, 782–792. [Google Scholar] [CrossRef] [PubMed]
- Wauters, J.; Baar, I.; Meersseman, P.; Meersseman, W.; Dams, K.; De Paep, R.; Lagrou, K.; Wilmer, A.; Jorens, P.; Hermans, G. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: A retrospective study. Intensive Care Med. 2012, 38, 1761–1768. [Google Scholar] [CrossRef]
- Koehler, P.; Bassetti, M.; Chakrabarti, A.; Chen, S.C.A.; Colombo, A.L.; Hoenigl, M.; Klimko, N.; Lass-Flörl, C.; Oladele, R.O.; Vinh, D.C.; et al. Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect. Dis. 2021, 21, e149–e162. [Google Scholar] [CrossRef]
- Hamam, J.; Navellou, J.C.; Bellanger, A.P.; Bretagne, S.; Winiszewski, H.; Scherer, E.; Piton, G.; Millon, L.; Collaborative RESSIF Group. New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU. Ann. Intensive Care 2021, 11, 41. [Google Scholar] [CrossRef]
- Egger, M.; Hoenigl, M.; Thompson, G.R., 3rd; Carvalho, A.; Jenks, J.D. Let’s talk about sex characteristics—As a risk factor for invasive fungal diseases. Mycoses 2022, 65, 599–612. [Google Scholar] [CrossRef] [PubMed]
- Schroeder, M.; Giese, M.; Wijaya, C.; Winterland, S.; Nuechtern, A.; Grensemann, J.; Matthews, H.; Wichmann, D.; Stamm, J.; Rohde, H.; et al. Comparison of four diagnostic criteria for invasive pulmonary aspergillosis—A diagnostic accuracy study in critically ill patients. Mycoses 2022, 65, 824–833. [Google Scholar] [CrossRef] [PubMed]
- Alanio, A.; Dellière, S.; Fodil, S.; Bretagne, S.; Mégarbane, B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir. Med. 2020, 8, e48–e49. [Google Scholar] [CrossRef]
- Lamoth, F.; Glampedakis, E.; Boillat-Blanco, N.; Oddo, M.; Pagani, J.L. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin. Microbiol. Infect. 2020, 26, 1706–1708. [Google Scholar] [CrossRef]
- Egger, M.; Bussini, L.; Hoenigl, M.; Bartoletti, M. Prevalence of COVID-19-Associated Pulmonary Aspergillosis: Critical Review and Conclusions. J. Fungi. 2022, 8, 390. [Google Scholar] [CrossRef]
- Prattes, J.; Koehler, P.; Hoenigl, M.; ECMM-CAPA Study Group. COVID-19 associated pulmonary aspergillosis: Regional variation in incidence and diagnostic challenges. Intensive Care Med. 2021, 47, 1339–1340. [Google Scholar] [CrossRef]
- Feys, S.; Lagrou, K.; Lauwers, H.M.; Haenen, K.; Jacobs, C.; Brusselmans, M.; Debaveye, Y.; Hermans, G.; Hoenigl, M.; Maertens, J.; et al. High burden of COVID-19-associated pulmonary aspergillosis (CAPA) in severely immunocompromised patients requiring mechanical ventilation. Clin. Infect. Dis. 2023, ciad546. [Google Scholar] [CrossRef] [PubMed]
- Asperges, E.; Novati, S.; Muzzi, A.; Biscarini, S.; Sciarra, M.; Lupi, M.; Sambo, M.; Gallazzi, I.; Peverini, M.; Lago, P.; et al. Rapid response to COVID-19 outbreak in Northern Italy: How to convert a classic infectious disease ward into a COVID-19 response centre. J. Hosp. Infect. 2020, 105, 477–479. [Google Scholar] [CrossRef] [PubMed]
- Oz, Y.; Kiraz, N. Diagnostic methods for fungal infections in pediatric patients: Microbiological, serological and molecular methods. Expert Rev. Anti-Infect. Ther. 2011, 9, 289–298. [Google Scholar] [CrossRef] [PubMed]
Table 1.
Population description. Continuous data are presented with median and interquartile ranges (1°–3° quartile) and categorical data with frequency and percentages. ICU: intensive care unit; NA: not available; CPAP: continuous positive air pressure; BAL: Bronchoalveolar lavage.
Table 1.
Population description. Continuous data are presented with median and interquartile ranges (1°–3° quartile) and categorical data with frequency and percentages. ICU: intensive care unit; NA: not available; CPAP: continuous positive air pressure; BAL: Bronchoalveolar lavage.
| Hospitalisation Registry (n = 196) | |
|---|---|
| Age [years] | 64 (53–71) |
| Sex | |
| Male | 139 (70.9) |
| Female | 57 (29.1) |
| Outcome | |
| Deceased | 66 (33.7) |
| Discharged | 130 (66.3) |
| Length of stay [days] | 26.1 (14.3–49.0) |
| ICU admission (NA: 80) | 52 (44.8) |
| Mechanical ventilation (NA: 82) | |
| CPAP | 18 (15.8) |
| Invasive | 47 (41.2) |
| Comorbidities | |
| Diabetes (NA: 83) | 20 (17.7) |
| Obesity (NA: 83) | 11 (9.7) |
| Solid tumour (NA: 84) | 13 (11.6) |
| Chronic Obstructive Pulmonary Disease (NA: 83) | 24 (21.2) |
| mAspICU and ECMM factors | |
| Compatible signs (NA: 84) | 83 (74.1) |
| Neutropenia: <0.5 × 109 [neu/L] before or at ICU admission (NA: 81) | 7 (6.1) |
| Cytotoxic agents (NA: 84) | 16 (14.3) |
| Steroids: 20 mg/day (NA: 83) | 98 (87.5) |
| Immunodeficiency (NA: 83) | 11 (9.7) |
| EORTC/MSG host factors | |
| Neutropenia: <0.5 × 109 [neu/L] for >10 days (NA: 80) | 7 (6.0) |
| Haematological malignancy | 25 (21.7) |
| Haematopoietic stem-cell transplantation (NA: 83) | 11 (9.7) |
| Solid organ transplant | 9 (7.8) |
| Steroids: 0.3 mg/kg/day for >3 weeks (NA: 83) | 37 (32.6) |
| T-immunosuppressant (NA: 83) | 12 (10.6) |
| Treatment with B-cell suppressors | 4 (3.5) |
| Acute graft-versus-host disease | 1 (0.9) |
| Inherited severe immunodeficiency (NA: 83) | 1 (0.9) |
| Radiological pattern (NA: 91) | |
| Atypical | 88 (83.8) |
| Normal | 12 (11.4) |
| Typical | 5 (4.8) |
| Galactomannan antigen | |
| Material (NA: 8) | |
| BAL | 80 (42.6) |
| Serum | 108 (57.4) |
| Positivity (NA: 7) | 28 (14.8) |
| Discrepancy BAL/serum positivity | 5 (2.6) |
| Median value (NA: 7) | 0.2 (0.2–2) |
| Cultures | |
| Material (NA: 88) | |
| Bronchonasopharyngeal aspirate | 6 (5.5) |
| Sputum | 10 (9.3) |
| Induced sputum | 1 (0.9) |
| Blood | 1 (0.9) |
| BAL | 90 (83.3) |
| Species (NA: 85) | |
| Aspergillus | 17 (15.2) |
| Candida | 58 (51.8) |
| Aspergillus + Candida | 17 (15.2) |
| mAspICU classification (NA: 85) | |
| Certain | 0 (0.0) |
| Putative | 20 (18.0) |
| Colonisation | 2 (1.8) |
| ECMM classification (NA: 85) | |
| Certain | 0 (0.0) |
| Probable | 19 (17.1) |
| Possible | 2 (1.8) |
| EORTC/MSG classification (NA: 84) | |
| Certain | 0 (0.0) |
| Probable | 10 (8.9) |
| Possible | 27 (24.1) |
| Treatment | |
| Decision to treat (NA: 86) | 33 (16.8) |
| Drug | |
| Echinocandin | 3 (6.5) |
| Fluconazole | 2 (4.3) |
| Voriconazole | 24 (12.2) |
| Isavuconazole | 2 (4.3) |
| Voriconazole + amphotericin B | 1 (2.2) |
Table 2.
The 2 × 2 tables showing the relationship between the decision to treat (DTT) and the classification according to mAspICU, ECMM and EORTC/MSG diagnostic criteria, simplified to binary criteria (patients to whom criteria are not applicable or are colonised; patients who have or might have pulmonary aspergillosis).
Table 2.
The 2 × 2 tables showing the relationship between the decision to treat (DTT) and the classification according to mAspICU, ECMM and EORTC/MSG diagnostic criteria, simplified to binary criteria (patients to whom criteria are not applicable or are colonised; patients who have or might have pulmonary aspergillosis).
| mAspICU | |||
| Colonisation/Not Applicable | Certain/Putative | ||
| Treatment | No | 74 | 4 |
| Yes | 16 | 13 | |
| ECMM | |||
| Not Applicable | Certain/Probable/Possible | ||
| Treatment | No | 73 | 5 |
| Yes | 16 | 13 | |
| EORTC/MSG | |||
| Not Applicable | Certain/Probable/Possible | ||
| Treatment | No | 57 | 22 |
| Yes | 16 | 13 | |
Table 3.
Concordance between DTT and mAspICU, ECMM and EORTC/MSG criteria expressed as Cohen’s κ coefficient. Green represents a concordance value with p < 0.001; red represents a concordance value with p > 0.05.
Table 3.
Concordance between DTT and mAspICU, ECMM and EORTC/MSG criteria expressed as Cohen’s κ coefficient. Green represents a concordance value with p < 0.001; red represents a concordance value with p > 0.05.
| Concordance (Expressed as Cohen’s κ Coefficient) | ||||
|---|---|---|---|---|
| DTT | mAspICU | ECMM | EORTC/MSG | |
| DTT | 0.46 | 0.44 | 0.16 | |
| mAspICU | 0.91 | 0.02 | ||
| ECMM | 0.00 | |||
| EORTC/MSG | ||||
Table 4.
Univariate analysis showing correlation between the criteria’s factors and the decision to treat. Significant p-values are in bold. DTT: decision to treat; NA: not available; ICU: intensive care unit.
Table 4.
Univariate analysis showing correlation between the criteria’s factors and the decision to treat. Significant p-values are in bold. DTT: decision to treat; NA: not available; ICU: intensive care unit.
| Factors | DTT Yes (n = 31) | DTT No (n = 81) | p Value |
|---|---|---|---|
| Neutropenia: <0.5 × 109 [neu/L] for >10 days | 3 (9.7) | 4 (4.9) | 0.39 |
| Neutropenia: <0.5 × 109 [neu/L] before or at ICU admission | 2 (6.5) | 5 (6.2) | 1 |
| Haematological malignancy | 8 (25.8) | 16 (19.8) | 0.66 |
| Haematopoietic stem-cell transplantation (NA: 1) | 5 (16.1) | 6 (7.4) | 0.17 |
| Solid organ transplant | 2 (6.5) | 7 (8.6) | 1 |
| Steroids: 0.3 mg/kg/day for >3 weeks (NA: 1) | 11 (35.5) | 25 (32.1) | 0.82 |
| Steroids: 20 mg/day (NA: 2) | 26 (90.3) | 69 (87.3) | 0.91 |
| T-immunosuppressant (NA: 1) | 5 (16.1) | 7 (8.6) | 0.42 |
| B-immunosuppressant | - | 4 (4.9) | 0.57 |
| Acute graft-versus-host disease | - | 1 (1.2) | 1 |
| Inherited severe immunodeficiency (NA: 1) | 1 (3.2) | - | 0.27 |
| Compatible signs (NA: 2) | 28 (90.3) | 54 (67.5) | 0.03 |
| Cytotoxic agents (NA: 1) | 3 (10.0) | 13 (16.2) | 0.55 |
| Immunodeficiency (NA: 1) | 2 (6.5) | 9 (11.1) | 0.72 |
| Atypical Radiologic pattern (NA: 9) | 5 (16.7) | 12 (16.7) | 1 |
| Galactomannan positivity | 10 (32.2) | 7 (8.6) | <0.001 |
| Positive culture of Aspergillus (NA: 40) | 17 (63.0) | 25 (56.8) | 0.79 |
Table 5.
Univariate analysis showing correlation between survival and the diagnostic criteria’s factors. Significant p-values are in bold. NA: not available; ICU: intensive care unit.
Table 5.
Univariate analysis showing correlation between survival and the diagnostic criteria’s factors. Significant p-values are in bold. NA: not available; ICU: intensive care unit.
| Factors | Survivors (n = 86) | Deceased (n = 26) | p Value |
|---|---|---|---|
| Neutropenia: <0.5 × 109 [neu/L] for >10 days | 5 (5.8) | 2 (7.7) | 0.66 |
| Neutropenia: <0.5 × 109 [neu/L] before or at ICU admission | 5 (5.8) | 2 (7.7) | 0.66 |
| Haematological malignancy | 16 (18.6) | 8 (30.8) | 0.29 |
| Haematopoietic stem-cell transplantation | 8 (9.3) | 3 (11.5) | 0.71 |
| Solid organ transplant | 8 (9.3) | 1 (3.8) | 0.68 |
| Steroids: 0.3 mg/kg/day for >3 weeks | 26 (30.2) | 11 (42.3) | 0.36 |
| Steroids: 20 mg/day (NA: 2) | 75 (87.2) | 22 (91.7) | 0.81 |
| T-immunosuppressant | 11 (12.8) | 1 (3.8) | 0.29 |
| B-immunosuppressant | 1 (1.2) | 3 (11.5) | 0.04 |
| Acute graft-versus-host disease | 1 (1.2) | - | 1 |
| Inherited severe immunodeficiency | 1 (1.2) | - | 1 |
| Compatible signs (NA: 1) | 63 (73.3) | 19 (76.0) | 0.99 |
| Cytotoxic agents (NA: 1) | 7 (8.2) | 9 (34.6) | 0.002 |
| Immunodeficiency | 7 (8.1) | 4 (15.4) | 0.28 |
| Atypical Radiologic pattern (NA: 10) | 16 (20.0) | 1 (4.5) | 0.11 |
| Galactomannan positivity | 12 (14.0) | 5 (19.2) | 0.73 |
| Positive culture of Aspergillus (NA = 41) | 30 (55.6) | 12 (70.6) | 0.41 |
| Treatment (NA: 2) | 26 (31.0) | 3 (12.5) | 0.12 |
| mAspICU (NA: 1) | 14 (16.3) | 6 (24.0) | 0.56 |
| ECMM (NA: 1) | 15 (17.4) | 6 (24.0) | 0.65 |
| EORTC/MSG | 25 (29.1) | 12 (46.2) | 0.16 |
Table 6.
Multivariate analysis showing correlation between survival and diagnostic criteria. Significant p-values are in bold. OR: odds ratio.
Table 6.
Multivariate analysis showing correlation between survival and diagnostic criteria. Significant p-values are in bold. OR: odds ratio.
| OR | 95% Confidence Interval | p Value | |
|---|---|---|---|
| All criteria | |||
| Cytotoxic agents | 0.18 | 0.04–0.76 | 0.019 |
| B-cell suppressants | 0.66 | 0.03–8.59 | 0.76 |
| Treatment | 7.12 | 1.67–43.71 | 0.016 |
| mAspICU | 0.42 | 0.01–7.04 | 0.564 |
| ECMM | 0.45 | 0.03–13.95 | 0.583 |
| EORTC/MSG | 0.53 | 0.18–1.59 | 0.243 |
| mAspICU | |||
| Cytotoxic agents | 0.17 | 0.04–0.62 | 0.008 |
| B-cell suppressants | 0.58 | 0.02–7.03 | 0.687 |
| Treatment | 6.17 | 1.49–36.81 | 0.023 |
| mAspICU | 0.22 | 0.05–0.89 | 0.035 |
| ECMM | |||
| Cytotoxic agents | 0.14 | 0.03–0.57 | 0.006 |
| B-cell suppressants | 0.64 | 0.03–7.80 | 0.738 |
| Treatment | 5.36 | 1.40–28.33 | 0.025 |
| ECMM | 0.23 | 0.06–0.92 | 0.036 |
| EORTC/MSG | |||
| Cytotoxic agents | 0.25 | 0.06–0.97 | 0.042 |
| B-cell suppressants | 0.48 | 0.03–5.33 | 0.572 |
| Treatment | 3.80 | 1.10–18.16 | 0.054 |
| EORTC | 0.61 | 0.22–1.76 | 0.343 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Asperges, E.; Pesare, R.; Bassoli, C.; Calia, M.; Lerta, S.; Citiolo, F.; Albi, G.; Cavanna, C.; Sacchi, P.; Bruno, R. The Prognostic Role of Diagnostic Criteria for COVID-19-Associated Pulmonary Aspergillosis: A Cross-Sectional Retrospective Study. Antibiotics 2024, 13, 150. https://doi.org/10.3390/antibiotics13020150
AMA Style
Asperges E, Pesare R, Bassoli C, Calia M, Lerta S, Citiolo F, Albi G, Cavanna C, Sacchi P, Bruno R. The Prognostic Role of Diagnostic Criteria for COVID-19-Associated Pulmonary Aspergillosis: A Cross-Sectional Retrospective Study. Antibiotics. 2024; 13(2):150. https://doi.org/10.3390/antibiotics13020150
Chicago/Turabian StyleAsperges, Erika, Rebecca Pesare, Cecilia Bassoli, Matteo Calia, Sonia Lerta, Francesco Citiolo, Giuseppe Albi, Caterina Cavanna, Paolo Sacchi, and Raffaele Bruno. 2024. "The Prognostic Role of Diagnostic Criteria for COVID-19-Associated Pulmonary Aspergillosis: A Cross-Sectional Retrospective Study" Antibiotics 13, no. 2: 150. https://doi.org/10.3390/antibiotics13020150
APA StyleAsperges, E., Pesare, R., Bassoli, C., Calia, M., Lerta, S., Citiolo, F., Albi, G., Cavanna, C., Sacchi, P., & Bruno, R. (2024). The Prognostic Role of Diagnostic Criteria for COVID-19-Associated Pulmonary Aspergillosis: A Cross-Sectional Retrospective Study. Antibiotics, 13(2), 150. https://doi.org/10.3390/antibiotics13020150
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
